Compare TW & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TW | GH |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9B | 20.6B |
| IPO Year | 2019 | 2018 |
| Metric | TW | GH |
|---|---|---|
| Price | $101.36 | $161.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | ★ $135.25 | $119.79 |
| AVG Volume (30 Days) | 1.5M | ★ 2.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 62.23 | 6.74 |
| EPS | ★ 1.81 | N/A |
| Revenue | $892,659,000.00 | ★ $982,021,000.00 |
| Revenue This Year | $18.07 | $33.30 |
| Revenue Next Year | $10.66 | $28.27 |
| P/E Ratio | $54.70 | ★ N/A |
| Revenue Growth | 15.10 | ★ 32.88 |
| 52 Week Low | $91.42 | $41.19 |
| 52 Week High | $141.12 | $174.08 |
| Indicator | TW | GH |
|---|---|---|
| Relative Strength Index (RSI) | 50.84 | 60.80 |
| Support Level | $95.30 | $152.64 |
| Resistance Level | $104.43 | $174.08 |
| Average True Range (ATR) | 3.46 | 7.80 |
| MACD | 0.36 | -1.27 |
| Stochastic Oscillator | 48.18 | 54.90 |
Founded in 1998 and headquartered in New York City, Tradeweb Markets is a leading fixed-income trading platform. While it does offer electronic processing for some voice-negotiated trades, the company focuses primarily on providing electronic trading networks that connect broker/dealers, institutional clients, and retail customers. While the company offers trading in a wide variety of products, the bulk of its business is in US and European government debt, mortgage-backed securities, interest-rate swaps, and US and international corporate bonds. The firm also sells fixed-income trading and price data, primarily through a deal with Refinitiv's Eikon service.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.